Skip to main content

BioAge Labs Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

BIOA$5.78+1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share information)

Three Months Ended · Nine Months Ended
September 30,September 30,
2024202320242023
Operating expenses:
Research and development$20,019$6,532$39,811$23,804
General and administrative4,7313,35513,02111,000
Total operating expenses24,7509,88752,83234,804
Loss from operations(24,750)(9,887)(52,832)(34,804)
Other income (expense), net:
Interest expense(388)(2,403)(2,048)(5,235)
Interest and other income2,0374995,5342,052
Loss from changes in fair value of warrants and derivative liabilities(306)(2,834)(384)(4,909)
Loss on extinguishment of debt——(250)—
Total other income (expense), net1,343(4,738)2,852(8,092)
Net loss$(23,407)$(14,625)$(49,980)$(42,896)
Net loss per share attributable to common stockholders, basic and diluted$(6.70)$(8.74)$(21.76)$(25.64)
Weighted-average common shares outstanding, basic and dilutive3,494,5801,672,7262,297,3971,672,701
Comprehensive loss:
Net loss(23,407)(14,625)(49,980)(42,896)
Foreign currency translation adjustment58355567
Total comprehensive loss$(23,349)$(14,590)$(49,925)$(42,829)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.